Hemi-central retinal vein occlusion as a rare manifestation of the hypercoagulable state in COVID-19
| Autor: | Amanda Milburn, Jose R. Russe-Russe, Alejandro Alvarez-Betancourt, Prachi Anand |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
retina medicine.medical_treatment venous thromboembolism Case Report Nasal congestion Targeted therapy Ophthalmoscopy Lethargy Central retinal vein occlusion Diabetes mellitus Retinal Vein Occlusion medicine Humans Fluorescein Angiography medicine.diagnostic_test business.industry SARS-CoV-2 COVID-19 General Medicine medicine.disease Fluorescein angiography eye diseases Surgery Female medicine.symptom business Kidney disease |
| Zdroj: | BMJ Case Reports |
| ISSN: | 1757-790X |
| Popis: | To date, COVID-19 has no definite effective targeted therapy, and management is primarily supportive. Central retinal vein occlusion (CRVO) is frequently caused by systemic risk factors posing hypercoagulable states. In April 2020, a female patient with a history of hypertension, diabetes mellitus and chronic kidney disease presented with 2 days of loose, watery stools, nasal congestion and severe lethargy. The patient denied dyspnoea or fever. A week after the initial symptoms, the patient reported decreased vision from the left eye. Dilated funduscopy and fluorescein angiography suggested hemi-CRVO. The patient refused intravitreal antivascular endothelial growth factor agents because of non-severe visual loss. Testing was positive for COVID-19 IgG antibodies; reverse transcription PCR was not available. Vision improved within 3 weeks of presentation. We recommend that clinicians keep a high suspicion for acute onset of thrombotic events in patients with COVID-19 and thrombotic predisposing risk factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|